Thermo Fisher Scientific Inc.. (2/20/09). "Press Release: Thermo Fisher Scientific FAIMS. Successful Application to Validated Bioanalytical Studies". San José, CA.

	Organisation	Thermo Fisher Scientific Inc. (NYSE: TMO)
	Group	Thermo Fisher (Group)
	Organisation 2	Deutsche Sporthochschule Köln
	Product	FAIMS technology
	Product 2	LC/MS (liquid chromatography/mass spectrometry)

Thermo Fisher Scientific Inc., the world leader in serving science, hosted its inaugural FAIMS (high-Field Asymmetric waveform Ion Mobility Spectrometry) meeting in Germany at the end of 2008. The goal of the event was to bring European FAIMS users together to discuss ways of improving the selectivity of liquid-chromatography/tandem mass spectrometry (LC-MS/MS) analysis. FAIMS eliminates interferences and significantly increases the selectivity of an analysis. Researchers attending the event showcased a number of breakthroughs enabled through their use of FAIMS technology, including the first validated FAIMS method for bioanalytical studies.

FAIMS allows researchers to filter ions of interest before introducing them into the mass spectrometer, and in doing so increases the selectivity of an assay before mass analysis is performed. The technique filters out background matrix noise and provides a cleaner signal and a better spectral quality than would be possible with LC-MS alone. FAIMS technology attracts a diverse range of customers, many of whom were represented at the meeting: large pharmaceutical companies, contract research organizations (CROs), agriculture/bioscience, universities, hospitals and even the world anti-doping agency accredited lab Deutsche SportHochSchule.

As Dr. Simon Szwandt of Thermo Fisher Scientific and chairperson of the event explained, "It's no accident that the first ever FAIMS meeting was held in Germany. That's where we're seeing the strongest response to this ground-breaking selectivity technology." The delegates, who came from Germany, the UK, Denmark and Switzerland and from companies such as A&M Labor, Roche and Sanofi-Aventis, participated in lively question and answer sessions and exchanged FAIMS information, anecdotes and experiences.

Dr. Axel Roemer of the German CRO A&M Labor presented the keynote lecture. He described A&M Labor's efforts to improve protein and peptide analysis, and presented the world's first validated method for peptide analysis using FAIMS-based LC-MS (LC-FAIMS-MS). Using peptides in rat serum, Roemer and colleagues have shown that LC-FAIMS-MS chromatograms offer greatly reduced chemical background compared to those produced without FAIMS. The technique enables complex matrix interferences, which prevent method validation in a traditional LC-MS assay, to be successfully removed, and leads to lower limits of detection as low as 10 pg/mL (100 times less than the 1 ug/mL LLOD offered by other ion mobility technologies). A&M Labor expects to be reporting on even better results at next year's meeting.

Dr. Michael Blackburn of Sanofi-Aventis gave a talk with the theme "big pharma with small molecules." During method validation for drug candidates that are undergoing preclinical trials, interferences commonly appear in the control matrices used. This can adversely affect the accuracy and precision of the bioanalytical method. Even with online sample clean-up and the high selectivity of LC-MS/MS, this interference can still be present and selectivity can be less than optimal. Blackburn and co-workers have shown that FAIMS cleans up chromatographic interferences with ease and have used FAIMS to successfully validate three assays in plasma from various species. In each case, FAIMS resulted in clean chromatograms with no interferences. The chromatographic peaks are easy to integrate and there is no confusion as to where the compound elutes. Indeed, in one analysis Blackburn showed that using FAIMS leads to a signal that is 4.5 times larger and a signal-to-noise ratio that is 2000 times better.

Coming this autumn, Thermo Fisher will host the 2009 EuroFAIMS meeting in Basel, Switzerland and Proteo-FAIMS 2009 in Toronto, Canada.

For more information about Thermo Scientific FAIMS solutions, please call +1 800-532-4752, e-mail analyze@thermofisher.com or visit www.thermo.com/faims.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

Record changed: 2011-12-29

Follow Us!

Top News

Upcoming Events

Associations

Partners

Thermo Fisher Scientific Inc.. (2/20/09). "Press Release: Thermo Fisher Scientific FAIMS. Successful Application to Validated Bioanalytical Studies". San José, CA.

More documents for Thermo Fisher (Group)